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Fluorescent imaging of colorectal tumor cells would improve tumor localization and 
allow intra-operative staging, facilitating stratification of surgical resections thereby 
improving patient outcomes. We aimed to develop and test fluorescent nanoparticles 
capable of allowing this in vivo. Dye-doped silica nanoparticles were synthesized. Anti-
CEA (carcinoembryonic antigen) or control IgGs were conjugated to nanoparticles 
using various chemical strategies. Binding of CEA-targeted or control nanoparticles 
to colorectal cancer cells was quantified in vitro, and in vivo after systemic-delivery 
to murine xenografts. CEA-targeted, polyamidoamine dendrimer-conjugated, 
nanoparticles, but not control nanoparticles, allowed strong tumor-specific imaging. 
We are the first to demonstrate live, specific, in vivo imaging of colorectal cancer 
cells using antibody-targeted fluorescent nanoparticles. These nanoparticles have 
potential to allow intra-operative fluorescent visualization of tumor cells.
Keywords:  colorectal cancer • dye-doped • IVIS imaging  • live tumor imaging • silica 
nanoparticles • tumor markers
Colorectal cancer resections are based on 
operations that have been performed for over 
100 years, involving a radical mesenteric 
basin resection encompassing primary tumor, 
vasculature and lymphatics [1]. However, this 
‘one size fits all’ approach may be inappropri-
ate in an increasing proportion of cases. Cur-
rently only approximately 35% of patients 
undergoing colorectal cancer resections have 
nodal metastases [2], yet all of them undergo 
this radical resection. National bowel cancer 
screening programs have led to increases in 
diagnoses of small, early stage cancers, such 
as polyp and Dukes’ A cancers [3]. These are 
less likely to have nodal metastases therefore 
resection with radical lymphadenectomy 
could be regarded as over-treatment. On the 
other hand, some have suggested that patients 
with nodal metastases may benefit from even 
more radical resections [4]. Unfortunately, at 
present there is no accurate method for assess-
ing nodal status pre- or intra- operatively. A 
further issue is that accurate localization of 
small tumors during laparoscopic surgery, 
which is now in routine use in many centers 
[5], is especially problematic because of a lack 
of tactile feedback. These problems highlight 
the need for intra-operative tumor imaging 
that would aid tumor localization, and could 
also allow intra-operative staging of nodal 
metastases and thereby allow surgeons to 
stratify resection radicality to each individual 
patient.
Laparoscopic surgery provides an ideal 
platform for intra-operative fluorescent imag-
ing. Camera systems can be modified simply 
to provide excitatory light of various wave-
lengths and fluorescent signals and white-
light images can be detected and overlaid 
on-screen for real-time surgical guidance 
[6]. While technologies required for physical 
imaging are relatively well developed, the bio-
logical and nanotechnological requirements 
have lagged behind. We have previously 
investigated that colorectal cancer biomarker 
is suitable in this context and have deter-
mined that the tumor marker carcinoembry-
onic antigen (CEA) provides the best sensi-
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tivity and specificity for colorectal cancer detection and 
localization [7]. We have now developed and validated 
a fluorescent nanoparticle that can target CEA to allow 
fluorescent tumor visualization. The requirements for 
such a particle are challenging. The particle must be 
bright enough to allow detection through tissue, while 
remaining sufficiently small to pass out of vasculature 
after intravenous delivery. Ideally, particles should have 
near-infrared emission wavelengths to increase tissue 
penetration and reduce auto fluorescence [8]. Particles 
must also have acceptable biotoxicity profiles, and resist 
photobleaching. We have focused on dye-doped silica 
nanoparticles, which have potential to meet these cri-
teria. For the dye, we used NIR-664, which is an iodo-
acetamide dye with suitable excitation and emission 
characteristics (672 and 694 nm, respectively), as well 
as relatively good stability across different pH values 
and high quantum efficiency (23%) [9]. A number of 
studies have been published in which dye-doped silica 
particles have been investigated as agents to label cancer 
cells fluorescently [10–12]. However, a key concern is the 
nonspecific binding potentially exhibited by particles 
when using some conjugations to antibodies, meaning 
that use of appropriate nontumor targeted controls is 
critical. Here, we show the first successful and robustly 
controlled use of systemically delivered, targeted fluo-
rescent nanoparticles for live in vivo colorectal cancer 
imaging. This represents a key stage in development of 
clinically practical intra-operative fluorescent imaging 
for colorectal cancer.
Materials & methods
Nanoparticle manufacture
Protocols were carried out at room temperature using 
Sigma-Aldrich (USA) reagents unless otherwise stated. 
Protocols were modified from previous publications 
[10–11,13]. ‘Wash’ steps: nanoparticles were pelleted by 
centrifugation (11,000 × g, 25 min), resuspended in 
wash solution using ultrasound sonication, repelleted 
and the supernatant discarded. 5 mg NIR664 (CA, 
USA) was dissolved in 6.25 ml 1-hexanol, and 3.25 μl 
(3-mercaptopropyl) triethoxysilane was added (stirred 
under nitrogen, 4 h). A total of 4.045 ml Triton X-100 
was added to 15 ml cyclohexane, 1.6 ml 1-hexanol, 
2 ml dye mixture and 960 μl water (stirred, 5 min). 
200 μl tetraethyl orthosilicate was added (stirred, 
30 min). One hundred and twenty microliters 28% 
[w/w] ammonia hydroxide was added (stirred, 24 h). 
150 μl tetraethyl orthosilicate was added (stirred, 
30 min). 20 μl ethanol was added and mixture was 
divided into two equal volumes before centrifugation 
(11,000 × g, 25 min). Particles were washed in ethanol 
(4×). 4 μl ethanol-suspended nanoparticles (2 mg/ml) 
were stirred with 4% (3-aminopropyl)triethoxysi-
lane (3 h). Particles were washed in ethanol (2×), and 
once in 2-(N-morpholino)ethanesulfonic acid buffer 
(MES), pH 7, before resuspension in MES pH 7 at 
2 mg/ml.
Antibodies
Humanized anti-CEA monocolonal antibody A5B7 
was supplied by the Cancer Research UK Biotherapeu-
tics Development Unit (Clare Hall Laboratories, UK). 
This antibody was raised against purified human CEA 
from human metastatic colon tumor tissue [14], and has 
been used previously in human clinical trials of CEA-
targeted therapies [15,16] and in molecular pathology 
studies of human tissue [7]. Mouse monoclonal anti-
digoxin IgG antibody (clone DI-22; Sigma-Aldrich, 
USA) was used as a negative, non-targeted, control.
Antibody conjugation
Succinimidyl-4-(N-maleimidomethyl)cyclohexane-
1-carboxylate (SMCC): 500 μl of 4.8 mg/ml anti-
CEA IgG antibody was added to 500 μl of 9.6 mg/ml 
2-mercaptoethylamine (2-MEA). The mixture was 
incubated at 37°C for 90 min and then cooled rapidly 
on ice. 2-MEA was then removed using a 100 kDa 
spin centrifuge filter (Millipore, Billerica, USA); the 
mixture was centrifuged in 0.1 M PBS (14,000 × g for 
2.5 min) and the eluent discarded. This was repeated 
seven times. The concentrated antibody solution was 
then retrieved by gentle centrifugation with the tube 
inverted (1000 × g for 30 s) and 0.1 M PBS was added 
to make the total volume up to 500 μl. The solution 
containing whole and reduced antibody fragments 
was reacted with nanoparticles immediately. 6 mg 
of fresh sulfo-SMCC was added to 4 ml of 1 mg/ml 
nanoparticles and stirred for 1 h. The maleimide-
activated particles were then washed twice in PBS 
(10,000 × g for 15 min) to remove unbound sulfo-
SMCC, and were resuspended at 2 mg/ml. The sam-
ple was split into two and 30 μg of reduced anti-CEA 
or antidigoxin was added to each tube. The reaction 
mixture was gently stirred for 2 h and then washed 
twice with PBS (6000 × g for 15 min). Finally, the 
particles were resuspended at 2 mg/ml and 0.1% 
(w/v) BSA added. The finished nanoparticles were 
stored in the dark at 4°C.
Poly[ethylene glycol] (PEG): A stock solution of 
250 mM NHS-PEG-maleimide (SM[PEG])
4
 was made 
by dissolving 100 mg in 680 μl DMSO. 8 μl of 250 
mM SM(PEG)
4
 solution was added to 5 ml of 2 mg/
ml nanoparticles and reacted for 30 min with gentle 
mixing. Unreacted linker was removed by washing par-
ticles twice with PBS (pH 7.2, 10,000 × g, 15 min) and 
resuspending them in PBS at 2 mg/ml. The sample was 
divided into two. 30 μl of either anti-CEA or antidi-
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goxin IgG was added for each mg of nanoparticles. The 
reaction mixture was incubated for 2 h with gentle mix-
ing. The particles were then washed twice with PBS and 
resuspended at 2 mg/ml. A total of 0.1% (w/v) BSA was 
added and they were stored in the dark at 4°C.
1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide 
hydrochloride (EDC): Nanoparticles were washed 
twice in DMF (10,000 × g, 15 min). They were then 
resuspended at 1 mg/ml in 15 ml 10% succinic anhy-
dride dissolved in DMF. This was incubated under 
argon for 4 h with gentle stirring. The carboxylated 
particles were then washed three-times with distilled 
water. 10 mg of carboxylated nanoparticles were sus-
pended in 5 ml of 0.1 M MES, 0.5 M NaCl, pH 6.0 
and 1.92 mg EDC and 5.43 mg sulfo-NHS were added. 
They were incubated for 15 min with gentle mixing, 
after which the reaction was quenched by addition of 
20 mM 2-MEA. Excess reactants were removed by 
washing the particles twice with PBS (6000 × g for 
10min) and resuspended at 2 mg/ml in 0.1 M PBS. 
Ten micrograms of either anti-CEA or antidigoxin IgG 
was added for each mg of nanoparticles. The reaction 
mixture was incubated for 2 h with gentle mixing. The 
particles were then washed twice with PBS and resus-
pended at 2 mg/ml. 0.1% (w/v) BSA was added and 
particles were stored in the dark at 4°C.
PAMAM dendrimer: A total of 41.7 mg sulfo-
NHS and 71.6 mg N-(3-dimethylaminopropyl)-
N′-ethylcarbodiimide were added to 1 μmol poly-
amidoamine (PAMAM) dendrimer generation 4.5 
(Dendritech, USA) dissolved in water, and the volume 
was made up to 1 ml with MES pH 6 (stirred, 25 min). 
Two milligram nanoparticles in MES pH 7 were added 
(stirred, 25 min). Particles were pelleted (16,000 × g, 8 
min), six times and washed in MES pH 7 (twice). Sam-
ples were divided into two before addition of either 10 
μg of A5B7 anti-CEA antibody (CRUK, UK) or anti-
digoxin IgG antibodies (Therapeutic Antibodies, UK). 
Particles and antibody were stirred (4 h) before addi-
tion of 100 μl of 0.1 M sodium hydroxide, pH 9.1. Par-
ticles were washed in 0.1 M PBS pH 7.2 (twice) before 
resuspension in 0.1 M PBS at 2 mg/ml. 2% (w/v) BSA 
was added and particles were stored (4°C, dark).
Scanning electron microscopy (SEM)
Images were captured using LEO1530 (Zeiss, Germany) 
or FEI Quanta (FEI, USA) field emission SEMs.
Tissue culture, confocal microscopy & image 
analysis
Cell lines were obtained from ATCC (USA). LS174T, 
LoVo and HCT116 cells were cultured in Advanced 
MEM (ATCC), F12K Nutrimix and RPMI1640 
(both Invitrogen, USA), respectively, supplemented 
with 10% FCS and 1% L-glutamine at 37°C in 5% 
CO
2
. Cells were seeded onto glass coverslips (Cellpath, 
UK) for 24 h. Cells were washed twice (PBS), fixed 
in 4% paraformaldehyde (30 min) and washed in PBS 
(3×). Coverslips were incubated in 0.1% (w/v) BSA 
(30 min) followed by PBS washes (3×). Coverslips were 
incubated with conjugated nanoparticles (1 mg/ml in 
PBS; 1 h, dark). Coverslips were washed in PBS (3×) 
and mounted using Depex (Waltham, USA). A Nikon 
A1R-A1 confocal microscope (Nikon, Japan) with 
NHS Elements software (v 4.0) was used. For each 
slide, cells were focused in phase mode in the center 
of one coverslip quadrant. Cy7 and phase filters were 
calibrated automatically for this first image only; set-
tings (laser power and gain) were saved and used for 
all subsequent images. Phase/Cy7 z-stack images were 
captured for this first quadrant; distances between 
optical sections were chosen to allow similar numbers 
of sections for each line and the whole cellular depth to 
be included (0.5, 0.2 and 0.4 μm for LS174T, LoVo and 
HCT116, respectively). The microscope stage was then 
moved to another quadrant, focused and examined 
under white light only (thereby minimizing selection 
bias) and a further z-stack captured. This was repeated 
so five z-stacks were captured from each coverslip, from 
approximately each quadrant center and one from the 
center of the entire coverslip. Single optical sections to 
be analyzed were taken from half way between base and 
top of the cells: at 5, 1.4 and 4.8 μm from the base for 
LS174T, LoVo and HCT116, respectively. Fluorescence 
was quantified using tiff images with ImageJ v1.42q 
(NIH Freeware, USA). Membrane fluorescence (per 
μm) was determined by measuring the cell circumfer-
ence, masking the cytoplasm and normalizing to back-
ground. This procedure was followed for five z-slices 
per cell line/particle type. Maximum image projec-
tion measurements were obtained by compressing all 
sections from each z-stack into a single image, and 
measuring mean fluorescences of the entire cell areas.
In vivo assays
All procedures were licensed by UK Home Office 
and were carried out in accordance with local ethi-
cal review. 4–6 weeks old BALB/c nu/nu female 
mice (Charles River, UK) were injected subcutane-
ously with 1.5 × 106 LS174T cells to the flank. When 
tumors reached approximately 10 mm diameter, mice 
were randomized to either CEA-targeted or control 
IgG conjugated-nanoparticles (50 mg/kg suspended 
in 100 μl PBS via tail vein under general anesthesia). 
Fluorescent images were captured using IVIS imaging 
(filters: excitation 672 nm, emission 694 nm; Perkin 
Elmer, USA) under anesthesia. Fluorescence measure-
ments (radiant efficiency in p/s/cm2/sr/μW/cm2) were 
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Figure 1. Nanoparticle characteristics. (A) Dye-doped silica nanoparticles conjugated to IgG antibodies via chemical linkers. 
1: fluorescent core; 2: silica shell; 3: biochemical linker; 4: antibody. (B) Field emission scanning electron microscope image of 
unconjugated particles (magnification: 1 × 105). (C) Diameters of 50 randomly-selected unconjugated particles or anti-CEA-
conjugated particles were quantified from electron microscope images (means with standard deviations; significance tested using 
unpaired t-tests).
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taken using Living Image (v4.3.1, Caliper Life Sci-
ences, USA); tumors were traced as regions of interest 
and mean quantum efficiency measurements taken, 
calibrated to background.
Statistics
Analyses were performed using in SPSS (SPSS, USA).
Results
Nanoparticle manufacture, antibody 
conjugation & physical characterisation
Protocols for manufacture of dye-doped silica nanopar-
ticles encasing NIR664 dye were developed from pub-
lished work [10–11,13]. Four separate protocols for conju-
gation of particles to antibodies were developed based 
on chemical linkers SMCC, PEG, EDC or PAMAM 
dendrimers, each of which has been reported to allow 
successful conjugation [13,17–19]. A schematic of the par-
ticles is shown in Figure 1A. Particles were characterized 
using scanning electron microscopy (Figure 1B). Uncon-
jugated particles had a mean diameter of 57 nm and 
were relatively homogeneous (SD 7 nm), indicating that 
particles were consistently of a suitable size for intrave-
nous delivery to tumors. Antibody-conjugated nanopar-
ticles (data shown for PAMAM dendrimer-conjugated 
only) had an equally suitable mean diameter of 71 nm.
PAMAM dendrimer-conjugation allows 
antibody-targeting of nanoparticles in vitro
We assessed whether our four conjugation strategies 
allowed targeting of nanoparticles to cancer cells using 
tumor-specific antibodies. Nanoparticles were conju-
gated to antibodies specific for either CEA, since this 
marker is highly sensitive and specific for colorectal can-
cer detection [7], or the glycoside digoxin, as a negative 
control. Binding of antibody-conjugated nanoparticles 
to three different colorectal cancer cell lines in vitro 
(LS174T, LoVo and HCT116) was quantified using con-
focal microscopy (Figure 2 & Supplementary Figure 1, see 
online at www.futuremedicine.com/doi/suppl/10.2217/
nnm.14.202). Fluorescence was first quantified on 
single optical sections through the middle of the cells. 
Nanoparticles conjugated using SMCC or PEG did 
not demonstrate any significant antibody-dependent 
tumor cell binding, although nonspecific binding was 
seen with both CEA- and control IgG-targeted particles 
(Supplementary Figure 1A & B). Similarly, nanoparticles 
conjugated using EDC showed very poor antibody-
dependent tumor cell binding, with only 1.7-fold greater 
binding of CEA-targeted nanoparticles as compared 
with control in only one cell line (LoVo, p = 0.017; 
Supplementary Figure 1C). More encouragingly, conju-
gation via PAMAM dendrimers allowed strong tumor-
specific targeting, with CEA-targeted nanoparticles 
demonstrating 12.3-, 8.0- and 3.2-fold greater fluores-
cence than control in LS174T, LoVo and HCT116 cells, 
respectively (p < 0.002; Figure 2A). Fluorescence was 
also quantified throughout the depth of the cells using 
maximum projection images, which compress the sig-
nals seen in individual optical section into one image. A 
similar pattern of successful CEA-targeted fluorescence 
was observed (p < 0.0002; Figure 2B).
CEA-targeted nanoparticles allow in vivo 
fluorescent imaging of colorectal xenografts
Next, we assessed whether these nanoparticles would 
allow in vivo tumor imaging. LS174T xenografts were 
established in nude mice and mice were injected intra-
venously with either CEA-targeted nanoparticles (n = 3) 
or control IgG nanoparticles (n = 3). Fluorescence was 
1227www.futuremedicine.com
Figure 2. Dye-doped silica nanoparticles conjugated to anti-carcinoembryonic antigen antibodies via PAMAM dendrimers allow 
specific fluorescent imaging of colorectal cancer cell lines in vitro. Three different colorectal cancer cell lines were incubated 
with either nanoparticles conjugated to anti-CEA, or to control antibodies. Images were collected using confocal microscopy and 
fluorescence was quantified. Representative images are shown (magnification: 63×): (A) phase contrast and fluorescent central 
optical sections; (B) phase contrast and maximum image projection. Graphs representing mean fluorescence (with standard 
deviations) are shown; significance was tested using unpaired t-tests. 
CEA: Carcinoembryonic antigen.
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quantified within specific organs/tissues (tumor or liver) 
noninvasively at time points from 1 min through to 72 h 
after injection. Hepatic fluorescence was observed in 
all mice, suggestive of hepatobiliary excretion, a feature 
1228 Nanomedicine (Lond.) (2015) 10(8)
Figure 3.  Carcinoembryonic antigen-targeted dye-doped silica nanoparticles allow live tumor-specific imaging 
in vivo. LS174T xenograft tumors were established in nu/nu balb-c mice. CEA-targeted or control IgG-conjugated 
particles were delivered systemically (50 mg/kg) and tumor fluorescence was measured using an in vivo imaging 
system small-animal imaging system at the time points shown. Representative images are shown of individual 
mice from each group (note these images were auto-exposed to enhance sensitivity, therefore depicted intensities 
are not comparable between images). Quantified data represent radiant efficiency for individual tumors in 
p/s/cm2/sr/μW/cm2. 
CEA: Carcinoembryonic antigen.
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observed previously [20]. Liver fluorescence was evident 
at 6 h (mean 8.01 × 107 p/s/cm2/sr/μW/cm2) and peaked 
at 24 h (8.98 × 107 p/s/cm2/sr/μW/cm2) before reduc-
ing (48 h: 7.42 × 107 p/sec/cm2/sr/μW/cm2 and 72 h: 
4.80 × 107 p/sec/cm2/sr/μW/cm2). Hepatic localization 
was confirmed by ex vivo imaging of isolated organs. 
There was no significant difference in liver fluorescence 
between mice injected with control particles and those 
injected with CEA-targeted particles at any time point (p 
ranging from 0.3 to 0.9, Mann–Whitney Test). Fluores-
cence in other mouse tissues was not seen for either con-
trol or CEA-targeted particles, demonstrating that the 
particles have negligible nonspecific or antibody directed 
binding to host cells. Substantial tumor fluorescence 
was detected in all mice injected with CEA-targeted 
nanoparticles from 6h post-injection (Figure 3). Mean 
tumor fluorescence increased over the whole experi-
ment from 6 h (mean 0.62 × 107 p/s/cm2/sr/μW/cm2) 
to 72 h (mean 4.74 × 107 p/s/cm2/sr/μW/cm2), although 
increases were only small after 48 h. Mice injected with 
control IgG-targeted nanoparticles showed no tumor 
fluorescence above background at any point (Figure 3). 
Fluorescence in the CEA-targeted tumors was signifi-
cantly greater than controls at every time point after and 
including 6 h (p < 0.0001, Wilcoxon Signed Rank Test). 
The continued accumulation of tumor fluorescence with 
the CEA-targeted nanoparticles for up to 72 h suggests 
that at least a proportion of the conjugated particles are 
stable in the circulation for a minimum of 72 h.
Discussion
Dye-doped silica nanoparticles, as used here, were 
originally described in a study targeting human leu-
kemia cells in vitro [11]. The fluorescent nanoparticles 
were conjugated using cyanogen bromide to leukemia 
cell-specific antibodies and the authors presented com-
parative images of cells incubated with targeted and 
control nanoparticles, although fluorescence was not 
quantified. However, critically, the controls consisted 
of ‘bare’ nanoparticles, with no targeting antibody 
or linkers attached, as opposed to the more appropri-
ate controls of nontargeting antibodies. This lack of 
robust controls represents a key and recurring issue 
in the field, which is of particular importance since 
we show nonspecific binding of antibody-conjugated 
nanoparticles is prevalent using some conjugation strat-
egies (Supplementary Figure 1) while antigen-specific 
targeting is more problematic.
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Cyanogen bromide conjugation appears not to have 
been repeated in any other relevant work, however, 
several groups have published studies with a variety of 
antibody-conjugations, including streptavidin-biotin 
[21], glutaraldehyde [10] and EDC [19,22]. SMCC has 
also been used in similar contexts to conjugate reduced 
antibodies to nanoparticles using the free sulfhydryl 
group, with the aim of increasing specific targeting 
by improving antigen-recognition site orientation [17]. 
Conjugation using heterobifunctional PEG is a fur-
ther option that can increase the particle circulating 
half-life by preventing reticulo-endothelial opsoniza-
tion [18]. More recently dendrimers have also been used 
as linkers between nanoparticles and antibodies [13]. 
We have tested four of these linkers, focusing on EDC, 
since this has been used in the overwhelming majority 
of studies, SMCC and PEG, on the basis of the poten-
tial advantages described above, and dendrimers. In 
order to test the abilities of these conjugations to direct 
antigen-specific binding of nanoparticles we have per-
formed carefully controlled and quantified analyses. 
We have previously demonstrated that CEA is the 
most appropriate biomarker for targeting colorectal 
cancer cells [7]. Therefore, here, we have used colorec-
tal cancer cells as a target for nanoparticles conjugated 
to anti-CEA antibodies or to antidigoxin antibodies, 
with digoxin representing a negative-control antigen 
not present within these cells. We found only den-
drimers to allow target-specific nanoparticle binding 
in all colorectal cell lines (Figure 2). Notably, SMCC 
allowed fairly strong binding without any suggestion 
of specificity, while EDC allowed weak specific bind-
ing in only one cell line (Supplementary Figure 1); 
these observations present concerns for the interpreta-
tion of previously published poorly controlled studies.
Having developed a fluorescent nanoparticle with 
genuine specificity for a surface antigen that is over-
expressed in cancers, we then examined the potential for 
this to be used to image tumors in vivo, using colorectal 
cancer xenografts. We delivered particles systemically 
to simulate a pre-operative intravenous injection. CEA-
targeted particles demonstrated, using in vivo imag-
ing, significant time-dependent accumulation within 
tumors that was entirely absent for control-targeted 
particles (p < 0.0001) (Figure 3). Only two other stud-
ies have investigated specific targeting of dye-doped 
silica nanoparticles to tumors via systemic delivery: 
Tivnan et al. [12] used dendrimer-conjugated particles 
targeted to neuroblastoma, while Soster et al. [23] used 
PEG- conjugated particles targeted to colorectal cancer 
metastases, both in murine xenograft models. How-
ever, both studies used ‘bare’ nanoparticles as controls, 
which are potentially problematic in terms of demon-
strating antigen-specific targeting, and both imaged 
fluorescence only on harvested organs ex vivo, which 
may relate to poor tissue penetration of fluorescence.
Conclusion
Our study is the first to use nanoparticles success-
fully to provide tumor-specific, live, in vivo fluorescent 
imaging in a murine model of colorectal cancer. Criti-
cally our work show great promise for clinical trans-
lation in the context of intra-operative imaging since 
fluorescence is bright, the antibody is humanized and 
has been used in clinical trials previously and silica 
nanoparticles appear to have favorable toxicity profiles. 
Furthermore, the technology is applicable to imag-
ing any tissue or pathology using antibodies targeting 
appropriate specific biomarkers.
Future perspective
Fluorescent laparoscopic imaging of primary colorec-
tal tumors and lymph node metastases is likely to 
become a routine procedure during colorectal resec-
tions within the medium term. However, demon-
strating specific tumor labeling remains problematic 
in many published studied. Further work is required 
using rigorous controls in order to optimize spe-
cific tumor labeling before such technologies can be 
translated into the clinic.
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Executive summary
Background
•	 Colorectal surgery could be aided by fluorescent labeling of tumor cells.
Materials & methods
•	 Dye-doped silica nanoparticles loaded with NIR664 dye were synthesized using a water-in-oil microemulsion 
technique.
•	 Anti-Carcinoembryonic antigen (CEA) IgGs or control IgGs were conjugated to nanoparticles using a variety of 
chemical strategies, including polyamidoamine dendrimers (PAMAM).
•	 Binding of CEA-targeted or control nanoparticles to colorectal cancer cells (LS174T, LoVo and HCT116) was 
quantified in vitro using confocal microscopy, or in vivo in the context of a murine xenograft model using 
noninvasive IVIS imaging.
Results
•	 CEA-targeted, PAMAM dendrimer-conjugated, nanoparticles allowed strong tumor-specific targeting in vitro, 
demonstrating up to 12-fold greater fluorescence than control IgG-targeted nanoparticles (p < 0.002).
•	 CEA-targeted nanoparticles demonstrated clear tumor-specific fluorescence in xenografts from 6 to 72 h after 
injection, as compared with only background fluorescence for control IgG-targeted nanoparticles (p < 0.0001).
Conclusion & future perspective
•	 These fluorescent nanoparticles show great promise for intra-operative imaging of colorectal cancers.
•	 The same technology could be harnessed for specific labeling of other pathologies using appropriate 
antibodies.
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